Cargando…
Using 5 consecutive years of NICE guidance to describe the characteristics and influencing factors on the economic evaluation of orphan oncology drugs
OBJECTIVE: Orphan oncology drugs used in this article were defined by the type of disease treated by drugs, as drugs used to treat rare diseases with a prevalence of ≤ 500 per million people per year. In this article, our concern was to explore focus on the economic evaluation of the National Instit...
Autores principales: | Shengnan, Duan, Zixuan, Lv, Na, Zhou, Weikai, Zhu, Yuanyuan, Yi, Jiasu, Liu, Ni, Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519130/ https://www.ncbi.nlm.nih.gov/pubmed/36187695 http://dx.doi.org/10.3389/fpubh.2022.964040 |
Ejemplares similares
-
Influencing Factors of Health Technology Assessment to Orphan Drugs: Empirical Evidence in England, Scotland, Canada, and Australia
por: Zhou, Na, et al.
Publicado: (2022) -
NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines Consortium
por: Ford, John A, et al.
Publicado: (2012) -
How long has NICE taken to produce Technology Appraisal guidance? A retrospective study to estimate predictors of time to guidance
por: Casson, Steven G, et al.
Publicado: (2013) -
Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs
por: Iskrov, Georgi, et al.
Publicado: (2016) -
Recent NICE guidance of interest to surgeons
por: Campbell, Bruce
Publicado: (2013)